Roche Holding AG (ROP) - Net Assets

Latest as of December 2025: CHF37.88 Billion CHF

Based on the latest financial reports, Roche Holding AG (ROP) has net assets worth CHF37.88 Billion CHF as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF100.70 Billion) and total liabilities (CHF62.82 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CHF37.88 Billion
% of Total Assets	37.62%
Annual Growth Rate	1.9%
5-Year Change	33.64%
10-Year Change	43.47%
Growth Volatility	21.69

Roche Holding AG - Net Assets Trend (1998–2025)

This chart illustrates how Roche Holding AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Roche Holding AG (1998–2025)

The table below shows the annual net assets of Roche Holding AG from 1998 to 2025.

Year	Net Assets	Change
2025-12-31	CHF37.88 Billion	+4.75%
2024-12-31	CHF36.16 Billion	+8.71%
2023-12-31	CHF33.26 Billion	+3.90%
2022-12-31	CHF32.02 Billion	+12.95%
2021-12-31	CHF28.34 Billion	-28.73%
2020-12-31	CHF39.77 Billion	+10.89%
2019-12-31	CHF35.87 Billion	+18.12%
2018-12-31	CHF30.37 Billion	+4.69%
2017-12-31	CHF29.01 Billion	+9.87%
2016-12-31	CHF26.40 Billion	+13.31%
2015-12-31	CHF23.30 Billion	+8.08%
2014-12-31	CHF21.56 Billion	+1.49%
2013-12-31	CHF21.24 Billion	+26.98%
2012-12-31	CHF16.73 Billion	+15.51%
2011-12-31	CHF14.48 Billion	+24.18%
2010-12-31	CHF11.66 Billion	+23.88%
2009-12-31	CHF9.41 Billion	-82.51%
2008-12-31	CHF53.82 Billion	+0.97%
2007-12-31	CHF53.31 Billion	+13.87%
2006-12-31	CHF46.81 Billion	+12.15%
2005-12-31	CHF41.74 Billion	+25.38%
2004-12-31	CHF33.29 Billion	+14.16%
2003-12-31	CHF29.16 Billion	+13.16%
2002-12-31	CHF25.77 Billion	-23.90%
2001-12-31	CHF33.87 Billion	+5.72%
2000-12-31	CHF32.04 Billion	+6.78%
1999-12-31	CHF30.00 Billion	+31.50%
1998-12-31	CHF22.82 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to Roche Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 125.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CHF48.84 Billion	144.48%
Common Stock	CHF107.00 Million	0.32%
Other Comprehensive Income	CHF-15.14 Billion	-44.80%
Total Equity	CHF33.80 Billion	100.00%

Roche Holding AG Competitors by Market Cap

The table below lists competitors of Roche Holding AG ranked by their market capitalization.

Company	Market Cap
UnitedHealth Group Incorporated NYSE:UNH	$256.27 Billion
Kweichow Moutai Co Ltd SHG:600519	$257.87 Billion
Raytheon Technologies Corp NYSE:RTX	$263.65 Billion
G2EV34 SA:G2EV34	$265.38 Billion
Wells Fargo & Company NYSE:WFC	$251.77 Billion
RTX Corporation NEO:RTX	$251.49 Billion
Philip Morris International Inc NYSE:PM	$245.63 Billion
Westpac Banking Corporation AU:WBCPI	$243.39 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Roche Holding AG's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 31,767,000,000 to 33,802,000,000, a change of 2,035,000,000 (6.4%).
Net income of 12,880,000,000 contributed positively to equity growth.
Dividend payments of 8,385,000,000 reduced retained earnings.
Share repurchases of 987,000,000 reduced equity.
Other comprehensive income decreased equity by 2,960,000,000.
Other factors increased equity by 2,474,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CHF12.88 Billion	+38.1%
Dividends Paid	CHF8.38 Billion	-24.81%
Share Repurchases	CHF987.00 Million	-2.92%
Other Comprehensive Income	CHF-2.96 Billion	-8.76%
Other Changes	CHF2.47 Billion	+7.32%
Total Change	CHF-	6.41%

Book Value vs Market Value Analysis

This analysis compares Roche Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 7.60x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 12.74x to 7.60x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1998-12-31	CHF25.11	CHF320.00	x
1999-12-31	CHF31.24	CHF320.00	x
2000-12-31	CHF32.69	CHF320.00	x
2001-12-31	CHF33.58	CHF320.00	x
2002-12-31	CHF24.81	CHF320.00	x
2003-12-31	CHF27.72	CHF320.00	x
2004-12-31	CHF33.20	CHF320.00	x
2005-12-31	CHF40.61	CHF320.00	x
2006-12-31	CHF45.76	CHF320.00	x
2007-12-31	CHF52.61	CHF320.00	x
2008-12-31	CHF51.66	CHF320.00	x
2009-12-31	CHF8.58	CHF320.00	x
2010-12-31	CHF11.05	CHF320.00	x
2011-12-31	CHF14.21	CHF320.00	x
2012-12-31	CHF16.95	CHF320.00	x
2013-12-31	CHF22.36	CHF320.00	x
2014-12-31	CHF22.70	CHF320.00	x
2015-12-31	CHF24.34	CHF320.00	x
2016-12-31	CHF27.80	CHF320.00	x
2017-12-31	CHF30.75	CHF320.00	x
2018-12-31	CHF32.12	CHF320.00	x
2019-12-31	CHF37.90	CHF320.00	x
2020-12-31	CHF42.01	CHF320.00	x
2021-12-31	CHF28.48	CHF320.00	x
2022-12-31	CHF34.99	CHF320.00	x
2023-12-31	CHF36.46	CHF320.00	x
2024-12-31	CHF39.61	CHF320.00	x
2025-12-31	CHF42.09	CHF320.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Roche Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 38.10%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 20.94%
• Asset Turnover: 0.61x
• Equity Multiplier: 2.98x
Recent ROE (38.10%) is below the historical average (38.14%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1998	20.27%	17.81%	0.44x	2.58x	CHF2.23 Billion
1999	21.38%	20.91%	0.39x	2.61x	CHF3.07 Billion
2000	31.32%	30.16%	0.41x	2.52x	CHF5.89 Billion
2001	12.76%	12.68%	0.39x	2.60x	CHF799.70 Million
2002	-19.35%	-13.54%	0.46x	3.08x	CHF-6.11 Billion
2003	13.02%	9.83%	0.52x	2.52x	CHF712.00 Million
2004	23.53%	21.24%	0.54x	2.06x	CHF3.82 Billion
2005	19.27%	18.95%	0.51x	1.99x	CHF3.24 Billion
2006	19.98%	18.74%	0.56x	1.89x	CHF3.94 Billion
2007	21.53%	21.16%	0.59x	1.72x	CHF5.23 Billion
2008	20.16%	19.66%	0.60x	1.71x	CHF4.52 Billion
2009	105.67%	15.87%	0.66x	10.12x	CHF7.05 Billion
2010	91.52%	18.25%	0.78x	6.44x	CHF7.72 Billion
2011	77.25%	21.97%	0.69x	5.09x	CHF8.13 Billion
2012	65.81%	20.97%	0.70x	4.47x	CHF8.09 Billion
2013	57.86%	22.97%	0.78x	3.22x	CHF9.23 Billion
2014	47.65%	18.71%	0.66x	3.86x	CHF7.37 Billion
2015	42.25%	17.58%	0.67x	3.61x	CHF6.77 Billion
2016	40.05%	18.19%	0.69x	3.21x	CHF7.18 Billion
2017	32.65%	15.49%	0.73x	2.90x	CHF5.99 Billion
2018	38.01%	17.65%	0.76x	2.84x	CHF7.74 Billion
2019	41.22%	21.17%	0.77x	2.54x	CHF10.22 Billion
2020	39.34%	24.51%	0.68x	2.37x	CHF10.66 Billion
2021	56.88%	22.18%	0.68x	3.77x	CHF11.48 Billion
2022	44.37%	18.87%	0.75x	3.15x	CHF9.62 Billion
2023	39.22%	19.02%	0.67x	3.09x	CHF8.57 Billion
2024	26.06%	13.27%	0.61x	3.20x	CHF5.10 Billion
2025	38.10%	20.94%	0.61x	2.98x	CHF9.50 Billion

Industry Comparison

This section compares Roche Holding AG's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $28,927,866,500
Average return on equity (ROE) among peers: 4.20%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Roche Holding AG (ROP)	CHF37.88 Billion	20.27%	1.66x	$254.60 Billion
COSMO Pharmaceuticals SA (COPN)	$393.73 Million	-6.22%	0.49x	$1.52 Billion
Novartis AG (NOVN)	$57.46 Billion	14.62%	0.66x	$241.30 Billion

About Roche Holding AG

SW:ROP Switzerland Drug Manufacturers - General

Market Cap

$278.72 Billion

CHF220.46 Billion CHF

Market Cap Rank

#64 Global

#1 in Switzerland

Share Price

CHF320.00

Change (1 day)

+2.07%

52-Week Range

CHF300.90 - CHF323.90

All Time High

CHF323.90